Expertise in
4
conditions

Lynda M. Foltz

St. Paul's Hospital, 
Vancouver, BC, CA 
Expertise in
4
conditions
St. Paul's Hospital, 
Vancouver, BC, CA 

Overview

Lynda Foltz practices practicing medicine in Vancouver, Canada.

Ms. Foltz is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Splenomegaly, Polycythemia Vera, and Essential Thrombocythemia.

She is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

St. Paul's Hospital, Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)
A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological, Drug
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

35 Total Publications

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026

Frequently Asked Questions about Lynda M. Foltz

Is Lynda M. Foltz a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Lynda M. Foltz is classified as an Elite expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lynda M. Foltz participate in research or clinical trials?

Yes. Lynda M. Foltz has published 35 articles and abstracts on conditions like Myelofibrosis. You can view a list of Lynda M. Foltz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Foltz's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile